Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm
- PMID: 19559818
- PMCID: PMC2838428
- DOI: 10.1016/j.cgh.2009.06.006
Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm
Conflict of interest statement
In the last three years Dr. Graham has received small amounts of grant support and/or free drugs or urea breath tests from Meretek, and BioHit for investigator initiated and completely investigator controlled research. Dr. Graham is a consultant for Novartis in relation to vaccine development for treatment or prevention of
Comment on
-
Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm.Clin Gastroenterol Hepatol. 2009 Nov;7(11):1156-63. doi: 10.1016/j.cgh.2009.03.032. Epub 2009 Apr 9. Clin Gastroenterol Hepatol. 2009. PMID: 19362611 Review.
References
-
- Fleming TR. Surrogate endpoints and FDA’s accelerated approval process. Health Aff (Millwood) 2005;24:67–78. - PubMed
-
- Moore A, Bjarnason I, Cryer B, Garcia-Rodriguez L, Goldkind L, Lanas A, Simon L. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol. 2009 - PubMed
-
- Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure stroke and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827–838. - PubMed
-
- Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet. 1990;336:370–371. - PubMed
-
- Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431–440. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources